Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991863 | 0.85 | PPARG (0.51) | FFAR1ALDH1A1ALOX15MAPK1SLC6A9 | |
| SCHEMBL8823321 | 0.83 | RXRA (0.41) | SMN1; SMN2NR1H4FFAR1RXRARXRB | |
| SCHEMBL21991923 | 0.81 | FNTA (0.51) | FFAR1EPHX2SLC6A9MEN1KMT2A | |
| SCHEMBL21991878 | 0.81 | MTNR1A (0.58) | L3MBTL1FFAR1KMT2AMTNR1AMTNR1B | |
| SCHEMBL8480831 | 0.81 | MTNR1A (0.44) | MAPTFFAR1KMT2AMTNR1AMTNR1B | |
| SCHEMBL23606001 | 0.81 | L3MBTL1 (0.49) | MAPTL3MBTL1FFAR1ALDH1A1LMNA | |
| SCHEMBL1418060 | 0.80 | MTNR1A (0.59) | MAPTFFAR1ALDH1A1LMNAALOX15 | |
| SCHEMBL10958161 | 0.79 | LDHA (0.55) | SMN1; SMN2TDP1MAPTFFAR1ALDH1A1 | |
| SCHEMBL2108300 | 0.79 | ALDH1A1 (0.50) | SMN1; SMN2MAPTFFAR1ALDH1A1LMNA | |
| SCHEMBL2108302 | 0.79 | ALDH1A1 (0.50) | SMN1; SMN2MAPTFFAR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020995-A2 | ZERO-ORDER MODIFIED RELEASE SOLID DOSAGE FORMS | Mallinckrodt Inc. (US) | 2009-02-11 | — | — | EP | claimed |
| WO-2007133583-A2 | ZERO-ORDER MODIFIED RELEASE SOLID DOSAGE FORMS | MALLINCKRODT INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240226007-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2024-07-11 | — | — | US | disclosed |
| EP-4333807-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2024-03-13 | — | — | EP | disclosed |
| EP-4333852-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Enalare Therapeutics Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023250141-A2 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023192602-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-07-06 | — | — | US | disclosed |
| US-20090110728-A1 | Zero-Order Modified Release Solid Dosage Forms | MALLINCKRODT INTERNATIONAL FINANCE S.A. (LU) | 2009-04-30 | — | — | US | disclosed |
| EP-2020995-A2 | ZERO-ORDER MODIFIED RELEASE SOLID DOSAGE FORMS | Mallinckrodt Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080254122-A1 | Polymer release system | EGALET A/S | 2008-10-16 | — | — | US | disclosed |
| US-20080254124-A1 | Controlled release composition | BM RESEARCH A/S | 2008-10-16 | — | — | US | disclosed |
| US-20080234352-A1 | Controlled release solid dispersions | EGALET A/S | 2008-09-25 | — | — | US | disclosed |
| WO-2007133583-A2 | ZERO-ORDER MODIFIED RELEASE SOLID DOSAGE FORMS | MALLINCKRODT INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20050019405-A1 | Controlled release composition | BM RESEARCH A/S | 2005-01-27 | — | — | US | disclosed |
| US-6787156-B1 | Controlled release composition | BM RESEARCH A/S (DK) | 2004-09-07 | — | — | US | disclosed |
| EP-0746310-B1 | CONTROLLED RELEASE COMPOSITION | BM RES AS (DK) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ADRA2C, MTNR1B, MTNR1A | SMN1; SMN2 1881/4885NR1H4 330/4885TDP1 3120/4885 |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | KCNN2, KCNN1, KCNN3 | SMN1; SMN2 630/4885NR1H4 3144/4885TDP1 4063/4885 |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ADRA2C, ADRA1B, CHRM3 | SMN1; SMN2 171/4885NR1H4 410/4885TDP1 2221/4885 |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | SDHA, NDUFB7, OTC | SMN1; SMN2 8/4885NR1H4 1811/4885TDP1 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.